Apixaban lowers the risk of stroke in subclinical atrial fibrillation

1. In this randomized controlled trial, apixaban lowered the risk of stroke or systemic embolism significantly more than aspirin in patients with subclinical atrial fibrillation.  2. Apixaban was associated with a higher risk of major bleeding than aspirin.  Evidence Rating Level: 1 (Excellent) Study Rundown: Symptomatic atrial fibrillation is a leading cause of stroke and stroke-related […]

The post Apixaban lowers the risk of stroke in subclinical atrial fibrillation first appeared on 2 Minute Medicine.